Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: John William Anderson who wrote (1693)	3/17/2003 3:01:24 PM
From: John William Anderson	Respond to of 1870

Regarding ISIS / LLY litmus test failure: Genta is going after a completely different protein and the concept is different. "Some analysts said the real cause of the trial's failure could be the target of the drug's activity, in this case a protein known as PKC-ALPHA. Related proteins may also have to be neutralized for such a drug to work, they said." Perhaps the BCL2 protein needs to be neutralized for ISIS' drug to work. see the URL: cbs.marketwatch.com